NCT06656936Not yet recruiting
The PharmFIT Study
Expanding Access to Colorectal Cancer Screening Through Community Pharmacies: The PharmFIT Study
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This study will conduct a randomized controlled trial to assess the impact of a pharmacy-based FIT intervention, Pharmacy-based FIT (PharmFIT), on colorectal cancer screening (CRC) screening rates in primary care patients who are not up to date on CRC screening. Through collaboration with community partners in North Carolina and the Pacific Northwest region, 1) the impact will be evaluated, 2) the implementation will be assessed, and 3) the costs of the PharmFIT intervention cost will be estimated. Patients (n=1,200) will be individually randomized to a usual care arm or a PharmFIT arm and we will determine whether there are statistically significant differences in CRC screening rates. Concurrently, a mixed methods approach will be used to assess a range of preliminary implementation outcomes, identify outcome barriers and facilitators, and identify implementation strategies to support future research. Also, the cost of PharmFIT will be calculated, using collaborative process flow diagramming (PFD) to inform micro-costing and budget impact analysis. Supported by preliminary work from the investigators, demonstrating widespread acceptability, feasibility, and preliminary effectiveness of PharmFIT, the rationale to conduct this hybrid 1 effectiveness-implementation trial1 is to generate new knowledge about pharmacy-based interventions to effectively increase CRC screening uptake and implementation. The central hypothesis is that the PharmFIT intervention will increase screening uptake by improving access to, and opportunities for, this preventive service through the involvement of a multidisciplinary, multisite, team-based care approach to CRC screening.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1500 (estimated)
- First submitted
- 16 Sept 2024
- Start date
- 1 Nov 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Colorectal cancer
- NCT number
- NCT06656936
What you commit to
- Study type: Interventional
- Planned participants: 1500
- From 1 Nov 2026 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous USPST CRC screening within recommended screening period: 1) Colonoscopy within the past 10 years, 2) FIT/FOBT/FIT-DNA test within the past 12 months, 3) Previous sigmoidoscopy within the past 5 years, 4) Previous CT colonography within the past 10 years, 5) Other CRC screening tests
- Previous positive FIT/FOBT/FIT-DNA
- Currently receiving hospice care
Other illness
- Family history of colorectal cancer
- Diagnosed with inflammatory bowel disease
- Diagnosis of Alzheimer's/other forms of severe dementia
- Diagnosed with end stage renal disease
- Current diagnosis of certain cancers (e.g., CRC, mesothelioma, glioblastoma, lung, pancreatic, and liver/bile duct)
Other
- Floaters/per diem employees
- Those who would object to having their interview audio recorded
- Those who would object to participation in evaluation surveys
- CRC screening is contraindicated
- Colorectal neoplasm or colorectal polyp
- Adenoma by biopsy
- Total or partial colectomy
- Resides in an assisted living facility
Who the study is looking for
- Age ≥18 years
- Employed at a participating primary care clinic or pharmacy
- Fluent in English
- Has access to a computer with internet
- Age 45-75 years
- Patient at a participating primary care facility (medical visit within last 18 months)
- Current resident of NC or WA state
- Not up to date with recommended screening (e.g., no colonoscopy within 10 years, no FIT-DNA test within 3 years; no FIT/FOBT within 12 months)
- English and Spanish speakers
- Has access to a computer or smartphone with internet
Age in the registry: 18 years to 99 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| Fred Hutch Cancer Center Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
Related publications
- Expanding access to colorectal cancer screening through community pharmacies: Study protocol for the PharmFIT™ randomized controlled trial.Contemp Clin Trials · 2026 · PMID 42632449
This page is information, not medical advice. Discuss any trial with your doctor.